Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Chemical Name: Revaprazan Hydrochloride; Revaprazan HCL CAS: 178307-42-1 API High Quality, Commercial Production| Item | Specifications |
| Appearance | White or Off-White Crystalline Powder |
| Solubility | Freely soluble in chloroform, dichlormeth; Soluble in Acetic acid; Slightly soluble in methanol, DMSO; Hardly soluble in acetone, ACN; Almost not soluble in 0.1mol/L NaOH solution. 0.1mol/L HCL solution. |
| Identification | Should be positively responded λ max 271nm 、205nm IR |
| Melting Point | 219.0~222.0℃ |
| Clarity and Color | Should be clear and colorless in dichlormeth |
| Chloride | ≤8.93% |
| Single Impurity | ≤0.10% |
| Total Impurities | ≤0.50% |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Sulfate | ≤20ppm |
| Arsenic | ≤10ppm |
| Heavy Metals | ≤10ppm |
| Assay | ≥99.0% |
| Test Standard | Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Revaprazan Hydrochloride |
| Synonyms | Revaprazan HCL |
| CAS Number | 178307-42-1 |
| CAT Number | RF-API48 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C22H24ClFN4 |
| Molecular Weight | 398.904 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Revaprazan Hydrochloride (CAS: 178307-42-1) with high quality. Revaprazan Hydrochloride reduces COX-2 expression and has significant anti-inflammatory actions activities in H. pylori infection. Revaprazan Hydrochloride in the treatment of duodenal ulcer, gastric ulcer and gastritis. Revaprazan Hydrochloride (also known as reversible proton pump inhibitors, potassium competitive acid blockers, p-CABs) is a new generation of reversible proton pump inhibitors and the only commercially available potassium competitive acid pump inhibitors or acid pump antagonists in the world. Developed by South Korean company Yuhan and with proprietary intellectual property rights, GLAxoSmithKline has obtained worldwide development and marketing licenses for the drug outside of South Korea and North Korea. The drug was approved by the South Korean FDA in 2007 to treat duodenal ulcers and gastritis.
